Capricor Therapeutics (CAPR): Millennium stake slips under 5%
Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have filed a Schedule 13G for Capricor Therapeutics (CAPR), reporting their beneficial ownership of 2,857,387 shares, which represents 4.9% of the outstanding common stock. Although the group acquired over 5% on August 17, 2026, their stake had fallen to 5% or less by the filing date. The filing specifies that the shares are under shared voting and dispositive power, with no sole control, and clarifies that beneficial ownership is disclaimed by the Millennium entities.
Bronstein, Gewirtz & Grossman LLC Urges Capricor Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR), alleging that the company made materially false and misleading statements to investors between December 17, 2025, and July 26, 2026. The lawsuit claims Capricor failed to disclose critical information regarding changes to its statistical analysis plan for Deramiocel's clinical data and the FDA's lack of agreement, potentially jeopardizing regulatory approval for its Duchenne muscular dystrophy treatment. Investors who suffered losses are encouraged to join the case by September 28, 2026.
Robbins LLP Urges CAPR Stockholders to Contact the Firm for Information About the Class Action Against Capricor Therapeutics, Inc.
Robbins LLP is urging stockholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR) to contact the firm regarding a securities class action lawsuit. The lawsuit alleges that Capricor misled investors about its lead product candidate Deramiocel, particularly concerning changes to its statistical analysis plan and the FDA's disagreement, which led to a significant drop in the company's stock price. Investors who purchased CAPR securities between December 17, 2025, and July 26, 2026, and suffered losses, may have legal rights and should seek appointment as lead plaintiff by September 28, 2026.
INVESTOR ALERT: Capricor Therapeutics, Inc. (CAPR) Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) on behalf of investors who purchased securities between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor made materially false and misleading statements regarding changes to the statistical analysis plan for Deramiocel clinical data and its compliance with FDA regulations, which led to a 64% stock drop after the FDA raised concerns. Investors with substantial losses have until September 28, 2026, to seek lead plaintiff status.
CAPR INVESTOR REMINDER: Capricor Therapeutics, Inc Investors Have Until September 28, 2026 To Contact Kirby McInerney LLP to Seek Lead Plaintiff Role
Kirby McInerney LLP is reminding investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) that they have until September 28, 2026, to contact the firm to seek a lead plaintiff role in a securities fraud class action lawsuit. The lawsuit alleges that Capricor made misleading statements regarding changes to its statistical analysis plan for Deramiocel, its lead product candidate, without FDA agreement, leading to significant stock price drops after negative FDA and advisory committee reports. Investors who suffered losses between December 17, 2025, and July 26, 2026, are encouraged to reach out to the firm.
CAPR INVESTOR REMINDER: Capricor Therapeutics, Inc. Investors Have Until September 28, 2026 To Contact Kirby McInerney LLP to Seek Lead Plaintiff Role
Kirby McInerney LLP reminds investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) that they have until September 28, 2026, to contact the firm to seek a Lead Plaintiff role in a securities fraud class action lawsuit. The lawsuit alleges Capricor made false and misleading statements and failed to disclose that it adopted changes to its statistical analysis plan for its lead product candidate, Duchenne muscular dystrophy treatment, without FDA agreement, leading to significant stock drops. Investors who purchased Capricor securities between December 17, 2025, and July 30, 2026, are encouraged to reach out to the law firm.
Robbins LLP Urges CAPR Stockholders to Contact the Firm for Information About the Class Action Against Capricor Therapeutics, Inc.
Robbins LLP has filed a securities class action against Capricor Therapeutics, Inc. (CAPR) on behalf of investors who purchased securities between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor misled investors about the FDA approval path for its lead product candidate, Deramiocel, by failing to disclose changes to the statistical analysis plan for clinical data. Investors are urged to contact Robbins LLP by September 28, 2026, to learn about their rights as lead plaintiff.
INVESTOR ALERT: Capricor Therapeutics, Inc. (CAPR) Investors With Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) on behalf of investors who purchased securities between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor made misleading statements regarding changes to its statistical analysis plan for Deramiocel clinical data and a lack of FDA agreement, which led to a significant stock drop. Investors with substantial losses have until September 28, 2026, to seek lead plaintiff status.
Lost Money on Capricor Therapeutics, Inc. (CAPR)? Join Class Action Suit Seeking Recovery - Contact The Gross Law Firm
The Gross Law Firm has issued a notice to shareholders of Capricor Therapeutics, Inc. (NASDAQ: CAPR) regarding a class action lawsuit. The suit alleges that Capricor Therapeutics made misleading statements about changes to its clinical trial analysis for Deramiocel without FDA agreement, potentially jeopardizing regulatory approval. Shareholders who purchased CAPR shares between December 17, 2025, and July 29, 2026, are encouraged to contact the firm to potentially join the lawsuit, with a lead plaintiff deadline of September 28, 2026.
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Capricor Therapeutics, Inc. (CAPR)
Bernstein Liebhard LLP has announced a securities fraud class action lawsuit against Capricor Therapeutics, Inc. (CAPR) on behalf of investors who purchased shares between December 17, 2025, and July 6, 2026. The lawsuit alleges that Capricor made false and misleading statements that artificially inflated its stock price, leading to significant losses for investors when the truth was revealed. Shareholders are encouraged to join the lawsuit, with a lead plaintiff deadline of September 28, 2026.
INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces
Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) for alleged securities law violations between December 17, 2025, and July 26, 2026. Investors who suffered substantial losses during this period have until September 28, 2026, to seek lead plaintiff status. The lawsuit claims Capricor made misleading statements regarding changes to the statistical analysis plan for its Deramiocel drug's Biologics License Application, which the FDA had not agreed to, leading to a significant risk of regulatory disapproval and subsequent stock price drops.
CAPR Stock News: Capricor Therapeutics Sued for Securities Fraud over Alleged Misrepresentations and Corresponding 64% Stock Drop
Capricor Therapeutics (CAPR) is facing a class action lawsuit for securities fraud, alleging misrepresentations regarding its drug Deramiocel and the integrity of its clinical data. The lawsuit claims that the company failed to disclose changes to its statistical analysis plan for Deramiocel's Biologics License Application, which the FDA had not approved, leading to a significant 64% stock drop. Investors have until September 28, 2026, to seek lead plaintiff status in the lawsuit.
CAPR Stock Alert: Capricor Therapeutics, Inc. (CAPR) Reports Q2 Earnings Amid Ongoing Securities Class Action Lawsuit - Hagens Berman
Hagens Berman is highlighting ongoing developments concerning Capricor Therapeutics, Inc. (CAPR) following its Q2 2026 earnings release, which notably omitted a management Q&A with analysts. The company is currently facing a securities fraud class action lawsuit, with a lead plaintiff deadline set for September 28, 2026. Allegations center on misleading statements regarding clinical trial data for its lead product, Deramiocel, and undisclosed changes to its statistical analysis plan, which led to a significant stock collapse after FDA briefing documents revealed these issues.
Deadline Alert: Capricor Therapeutics, Inc. (CAPR)
Glancy Prongay Wolke & Rotter LLP is reminding investors of Capricor Therapeutics, Inc. (CAPR) about a September 28, 2026 deadline to file as lead plaintiff in a securities fraud lawsuit. The lawsuit alleges that Capricor made misleading statements regarding changes to its statistical analysis plan for Deramiocel clinical data, which the FDA had not agreed to, leading to significant stock declines after negative FDA briefing documents and an advisory committee vote. Investors who purchased Capricor securities between December 17, 2025, and July 26, 2026, are urged to contact the firm.
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Average Rating of "Hold" from Brokerages
Capricor Therapeutics (NASDAQ:CAPR) has received an average "Hold" rating from eleven brokerages, with an average one-year price target of $29.15. Recent analyst adjustments include downgrades from "Buy" to "Hold" or "Neutral" by several firms, while one upgraded the stock to "Overweight." The company faces ongoing securities class action lawsuits alleging misstatements regarding its lead candidates and has reported a recent quarterly loss exceeding analyst expectations.
CAPR Stock Alert: Capricor Therapeutics, Inc. (CAPR) Reports Q2 Earnings Amid Ongoing Securities Class Action Lawsuit – Hagens Berman
Hagens Berman has highlighted developments regarding Capricor Therapeutics (NASDAQ: CAPR) following the company's Q2 2026 earnings release, which notably omitted a Q&A session with analysts. The firm encourages investors who suffered substantial losses to submit their information due to an active securities fraud class action lawsuit. The lawsuit alleges Capricor made misleading statements about clinical trial data and regulatory pathways for its lead product candidate, Deramiocel, leading to significant stock volatility.
Deadline Alert: Capricor Therapeutics, Inc. (CAPR)
Glancy Prongay Wolke & Rotter LLP is reminding investors of Capricor Therapeutics, Inc. (CAPR) about an upcoming September 28, 2026 deadline to file a lead plaintiff motion in a class action lawsuit. The lawsuit alleges securities fraud, stemming from the FDA's critical briefing documents concerning Capricor's cell therapy for Duchenne muscular dystrophy and subsequent negative stock performance. Investors who suffered losses between December 17, 2025, and July 26, 2026, are urged to contact the firm.
Capricor Therapeutics Soars As FDA Keeps Deramiocel Path Alive
Capricor Therapeutics (CAPR) stock surged after the FDA agreed to review an amended filing for its Duchenne muscular dystrophy drug, deramiocel, focusing on upper-limb function. Cantor Fitzgerald upgraded CAPR to Overweight with a significantly raised price target of $28. Despite no revenue and widening losses, the company holds about $238M in cash, providing a 12-month runway, making it a catalyst-driven trading stock.
Capricor Therapeutics (CAPR) Could Be 89% Undervalued Following Deramiocel And Loss Concerns
Capricor Therapeutics (CAPR) is under scrutiny after reporting wider Q2 2026 losses and ongoing legal/regulatory questions regarding its Duchenne muscular dystrophy candidate, Deramiocel. Despite recent share price volatility, with jumps of 58% in one day and 73% in seven days, the stock is still down year-to-date. A "most followed narrative" suggests Capricor is 88.5% undervalued, assigning a fair value of $58, driven by the potential of its exosome platform beyond Deramiocel.
CAPR INVESTOR ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit before September 28, 2026 Deadline
Robbins Geller Rudman & Dowd LLP announced a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) for purchasers of its securities between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor made misleading statements regarding changes to the statistical analysis plan for its lead product candidate, Deramiocel, without FDA agreement, leading to significant stock price drops. Investors with substantial losses have until September 28, 2026, to seek appointment as lead plaintiff.
Bronstein, Gewirtz & Grossman LLC Urges Capricor Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR), alleging that the company made materially false and misleading statements regarding its Duchenne muscular dystrophy treatment, Deramiocel. The lawsuit claims that Capricor adopted unauthorized changes to its statistical analysis plan for clinical data and that the FDA had not agreed to these changes before the company resubmitted its Biologics License Application, creating a significant risk that Deramiocel would not receive regulatory approval. Investors who purchased Capricor securities between December 17, 2025, and July 26, 2026, are encouraged to join the class action by September 28, 2026.
Kaplan Fox Deadline Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Have Until September 28, 2026 to Seek a Lead Plaintiff Role
Kaplan Fox & Kilsheimer LLP has announced a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) for investors who purchased securities between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor made undisclosed changes to its statistical analysis plan for its Dermamiocel Biologics License Application, leading to a significant stock price drop on July 27, 2026. Investors have until September 28, 2026, to seek a lead plaintiff role in the case.
Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline
Kahn Swick & Foti, LLC (KSF) has announced a class action securities lawsuit against Capricor Therapeutics, Inc. (NasdaqGS: CAPR) on behalf of investors who purchased securities between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor failed to disclose material information, specifically regarding changes to the statistical analysis plan for its product candidate, Deramiocel, which the FDA deemed "post-hoc and exploratory." Investors have until September 28, 2026, to apply for lead plaintiff status.
CAPRICOR THERAPEUTICS, INC. 2026: Revenue $14.08M, EPS ($0.7) — 10-Q Summary
Capricor Therapeutics reported its 2026 quarterly results, showing a significant increase in revenue to $14.08M from $5.67M a year prior, alongside an increased net loss of ($40.73M) and a diluted loss per share of ($0.7). The company is progressing with its BLA for Deramiocel, preparing for a potential launch, and advancing its exosome platform, while also engaged in arbitration regarding U.S. distribution pricing.
Capricor Therapeutics, Inc. (CAPR) Investors: September 28, 2026, Deadline in Securities Fraud Class Action Lawsuit – Contact Kessler Topaz Meltzer & Check, LLP
Kessler Topaz Meltzer & Check, LLP announces a securities fraud class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR). Investors who purchased CAPR securities between December 17, 2025, and July 26, 2026, have until September 28, 2026, to seek lead plaintiff status. The lawsuit alleges Capricor made material misstatements and omissions regarding changes to its lead product candidate's statistical analysis plan and FDA compliance, which led to a significant stock drop after the FDA raised concerns.
CAPR Stock Jumps As Lancet Data And Upgrade Shift Odds
Capricor Therapeutics (CAPR) stock surged by 97.39% following the publication of positive Phase 3 HOPE-3 trial data in The Lancet, showing its drug deramiocel slowed upper-limb decline in Duchenne muscular dystrophy. This scientific validation, coupled with an FDA Biologics License Application (BLA) under active review and an upcoming PDUFA decision on August 22, 2026, has led to analyst upgrades and increased trader interest. Despite being pre-revenue with significant cash burn, Capricor holds substantial cash reserves, positioning it as a high-volatility, catalyst-driven biotech stock ahead of its regulatory decision.
Capricor Therapeutics Faces Securities Lawsuit
Capricor Therapeutics (NASDAQ: CAPR) is facing a federal securities class action lawsuit alleging that the company made misleading statements regarding the regulatory prospects of its investigational cell therapy, deramiocel, for Duchenne muscular dystrophy. The lawsuit centers on alleged undisclosed changes to statistical analysis plans and the FDA's disagreement with these changes, which came to light through FDA briefing materials and an advisory panel meeting that questioned the therapy's effectiveness. Investors have until September 28, 2026, to seek appointment as lead plaintiff in the case.
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit
The Rosen Law Firm has announced a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) on behalf of investors who purchased securities between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor made materially false and misleading statements regarding changes to the statistical analysis plan for Deramiocel's clinical data and the FDA's agreement to these changes, leading to a significant risk in regulatory approval for the cell therapy. Investors are encouraged to join the lawsuit by September 28, 2026, to potentially recover damages.
Capricor: Q2 Earnings Snapshot
This article provides a brief "Q2 Earnings Snapshot" for Capricor. The full content of the article is not available beyond the title, indicating it may be a placeholder or an article with minimal information.
Earnings call transcript: Capricor Therapeutics Q2 2026 loss narrows focus to FDA path
Capricor Therapeutics reported a wider-than-expected Q2 2026 loss of $0.70 per share but saw its stock surge 83.6% after hours due to positive investor focus on its updated regulatory strategy for deramiocel, its Duchenne muscular dystrophy treatment. The company announced the FDA is open to reviewing a revised Biologics License Application (BLA) amendment, focusing on an upper limb skeletal muscle indication, which aligns with the HOPE-3 trial's primary endpoint. Capricor's financial results reflect heavy investment in clinical, regulatory, and manufacturing activities, with no commercial revenue yet.
Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Reed Kathrein at Hagens Berman Sobol Shapiro LLP Before Application Deadline
Hagens Berman is encouraging investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) who suffered substantial losses to come forward regarding a securities fraud class action lawsuit. The lawsuit alleges that Capricor made false and misleading statements about the clinical trial data and regulatory pathway for its lead product candidate, Deramiocel, leading to a significant stock drop after an FDA briefing document revealed changes to the statistical analysis plan. Investors have until September 28, 2026, to apply for lead plaintiff status.
Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Capricor Therapeutics announced its second-quarter 2026 financial results, highlighting that its Deramiocel Biologics License Application (BLA) is under active FDA review despite a mixed Advisory Committee outcome regarding its efficacy for cardiomyopathy in Duchenne Muscular Dystrophy (DMD). The company reported approximately $238 million in cash and marketable securities and noted that HOPE-3 Phase 3 results, published in The Lancet, achieved the primary endpoint of upper limb function. Capricor plans to continue working with the FDA on a path forward for Deramiocel and is advancing commercial readiness at a slower pace pending regulatory clarity.
Capricor Therapeutics Lawsuit Focuses on Deramiocel Disclosures After CAPR Stock Drops
Capricor Therapeutics is facing a federal securities lawsuit alleging that the company failed to disclose crucial information regarding changes in the statistical analysis plan for Deramiocel, its lead therapy candidate. The lawsuit claims that these omissions, particularly concerning FDA interactions and data analysis, led to significant drops in CAPR's stock price after FDA briefing documents and an advisory committee vote raised concerns about the drug's efficacy. Investors who purchased securities between December 17, 2025, and July 26, 2026, are covered by the suit, which alleges the company's positive statements about Deramiocel's regulatory path were misleading.
INVESTOR ALERT: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP has announced a shareholder class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) for alleged violations of the Securities Exchange Act of 1934. Investors who purchased Capricor securities between December 17, 2025, and July 26, 2026, and suffered substantial losses, have until September 28, 2026, to seek appointment as lead plaintiff. The lawsuit claims Capricor made false and misleading statements regarding changes to the statistical analysis plan for its lead product candidate, Deramiocel, without FDA agreement, leading to significant stock price drops after FDA briefing documents and an advisory committee meeting revealed concerns about the drug's effectiveness.
Capricor Therapeutics Shareholder Alert: ClaimsFiler
ClaimsFiler reminds investors of the September 28, 2026, lead plaintiff deadline in a class action lawsuit against Capricor Therapeutics, Inc. (CAPR). The lawsuit alleges the company failed to disclose material information regarding changes to its statistical analysis plan for Deramiocel, leading to an unfavorable FDA review and a significant stock drop. Investors who purchased Capricor securities between December 17, 2025, and July 26, 2026, are encouraged to seek legal counsel.
Bronstein, Gewirtz & Grossman LLC Urges Capricor Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Bronstein, Gewirtz & Grossman, LLC has filed a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) on behalf of investors who purchased securities between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor made false and misleading statements concerning changes to the statistical analysis plan for Deramiocel's clinical data and the FDA's knowledge of these changes, creating a significant risk that the drug would not receive regulatory approval for Duchenne muscular dystrophy. Investors who suffered losses are encouraged to join the case by September 28, 2026, with the firm operating on a contingency fee basis.
CAPRICOR INVESTOR ALERT: Bragar Eagel & Squire, P.C.
Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ:CAPR) on behalf of investors who purchased securities between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor made false and misleading statements and failed to disclose critical information regarding changes to the statistical analysis plan for Deramiocel and the FDA's stance on these changes, which posed a significant risk to regulatory approval. Investors have until September 28, 2026, to apply to be lead plaintiff.
CAPR UPCOMING DEADLINE: Levi & Korsinsky Alerts Capricor Therapeutics, Inc. Stockholders of Securities Class Action - Contact the Firm
Levi & Korsinsky, LLP has filed a securities class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) on behalf of investors who purchased securities between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor Therapeutics' shares collapsed after FDA briefing documents revealed issues with the HOPE-3 study's statistical analysis plan and an advisory committee voted against the efficacy of deramiocel, leading to significant stock price declines. Investors who suffered losses during this period are urged to contact the firm to determine their eligibility to recover losses.
Capricor Therapeutics, Inc. Notice of September 28, 2026
Hagens Berman has filed a securities fraud class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) alleging that the company made false statements regarding its lead product candidate, Deramiocel, for Duchenne muscular dystrophy. The lawsuit claims Capricor failed to disclose changes to its statistical analysis plan without FDA agreement, leading to a significant stock price collapse. Investors who suffered losses between December 17, 2025, and July 26, 2026, are encouraged to contact Hagens Berman before the lead plaintiff deadline of September 28, 2026.
CAPR INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP has announced a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) for purchasers or acquirers of its securities between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor and its executives made false and misleading statements and failed to disclose critical information regarding changes to the statistical analysis plan for their lead product candidate, Deramiocel, and the FDA's disagreement with these changes. Investors with substantial losses have until September 28, 2026, to seek appointment as lead plaintiff in the case.
CAPR INVESTOR ALERT: Capricor Therapeutics Securities Class Action Filed; September 28, 2026 Lead Plaintiff Deadline - Kehoe Law Firm
Kehoe Law Firm has filed a securities class action lawsuit against Capricor Therapeutics (NASDAQ: CAPR) on behalf of investors who purchased securities between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor made misleading statements by changing the statistical analysis plan for Deramiocel's clinical data without FDA agreement, thereby risking regulatory approval. Investors who suffered losses and acquired securities during the Class Period have until September 28, 2026, to move for lead plaintiff status.
CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law
Schall, Brown & Schwartz LLP (SBS) is reminding investors of a class action lawsuit against Capricor Therapeutics, Inc. (CAPR) for alleged securities fraud. The lawsuit claims Capricor made false and misleading statements regarding changes to the statistical analysis plan for Deramiocel's clinical data, potentially jeopardizing FDA approval. Shareholders who purchased CAPR shares between December 17, 2025, and July 26, 2026, are encouraged to contact SBS Law to discuss leading the lawsuit.
Robbins LLP Urges CAPR Stockholders Who Lost Money Investing in Capricor Therapeutics, Inc. to Contact the Firm for Information About Leading the Class Action
Robbins LLP is informing investors who lost money in Capricor Therapeutics, Inc. (NASDAQ: CAPR) between December 17, 2025, and July 26, 2026, about a securities class action lawsuit. The lawsuit alleges Capricor misled investors regarding the FDA approval path for its lead product, Deramiocel, by failing to disclose changes to its statistical analysis plan that the FDA had not agreed upon. Investors are urged to contact Robbins LLP by September 28, 2026, to learn about leading the class action.
CAPR Investor Announcement: Capricor Therapeutics Sued on behalf of Investors to Recover Losses after Clinical Data Leads to 64% Stock Drop
Bleichmar Fonti & Auld LLP has filed a class action lawsuit against Capricor Therapeutics, Inc. (CAPR) for securities fraud. The lawsuit alleges that Capricor made false statements regarding its lead product candidate, Deramiocel, and the integrity of its clinical data, which led to a 64% stock drop. Investors have until September 28, 2026, to seek appointment as lead plaintiff in the case.
CAPR Investor Announcement: Capricor Therapeutics Sued on behalf of Investors to Recover Losses after Clinical Data Leads to 64% Stock Drop
A class action lawsuit has been filed against Capricor Therapeutics, Inc. (NASDAQ: CAPR) and its executives for securities fraud, alleging misstatements about Deramiocel and the integrity of its clinical data. The lawsuit follows a significant 64% stock drop on July 27, 2026, after FDA briefing documents raised concerns about changes to the statistical analysis plan for Deramiocel's Biologics License Application. Investors who purchased Capricor securities are encouraged to contact Bleichmar Fonti & Auld LLP by the September 28, 2026 lead plaintiff deadline.
Kaplan Fox Encourages Investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) to Contact the Firm Before Lead Plaintiff Deadline on September 28, 2026
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) on behalf of investors who purchased securities between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor's stock price dropped significantly after the FDA released briefing documents questioning changes to the company's statistical analysis plan for its Dermamiocel BLA. Investors who suffered losses are encouraged to contact Kaplan Fox before the lead plaintiff deadline of September 28, 2026.
Kaplan Fox Encourages Investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) to Contact the Firm Before Lead Plaintiff Deadline on September 28, 2026
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) on behalf of investors who purchased securities between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor made undisclosed changes to its statistical analysis plan for its Dermamiocel Biologics License Application, causing a significant stock price drop. Investors are encouraged to contact Kaplan Fox before the lead plaintiff deadline of September 28, 2026.
Kaplan Fox Encourages Investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) to Contact the Firm Before Lead Plaintiff Deadline on September 28, 2026
Kaplan Fox & Kilsheimer LLP has announced a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) for investors who purchased securities between December 17, 2025, and July 26, 2026. The lawsuit stems from allegations that Capricor made undisclosed changes to its statistical analysis plan for its Dermamiocel BLA, leading to a significant stock price drop after the FDA briefing documents were released. Investors are encouraged to contact Kaplan Fox before the lead plaintiff deadline of September 28, 2026.
Kaplan Fox Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Who Suffered Losses to a Securities Class Action – Deadline is September 28, 2026
Kaplan Fox & Kilsheimer LLP has filed a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) on behalf of investors who purchased securities between December 17, 2025, and July 26, 2026. The lawsuit alleges that Capricor made unauthorized changes to its statistical analysis plan for its Dermamiocel Biologics License Application, leading to a significant stock price drop on July 27, 2026. Investors who suffered losses are encouraged to contact Kaplan Fox, with the lead plaintiff deadline set for September 28, 2026.
CAPR Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, September 28, 2026 Lead Plaintiff Deadline
Hagens Berman has filed a securities fraud class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR), encouraging investors who suffered substantial losses to come forward. The lawsuit alleges that Capricor made false and misleading statements about its Duchenne muscular dystrophy drug, Deramiocel, particularly concerning undisclosed changes to its statistical analysis plan for the HOPE-3 trial. The FDA's briefing document revealed these changes and indicated that the trial did not meet its primary and secondary efficacy endpoints, leading to a significant 64% drop in Capricor's stock price.
